Skip to main content
TipRanks
Go Ultimate75% OFF

Arcturus Therapeutics (ARCT) Stock Statistics & Valuation Metrics

2,165 Followers

Total Valuation

Arcturus Therapeutics has a market cap or net worth of $240.96M. The enterprise value is $226.39M.

Market Cap
$240.96M
Enterprise Value
$226.39M

Share Statistics

Arcturus Therapeutics has 28,822,514 shares outstanding. The number of shares has decreased by -2.65% in one year.

Shares Outstanding
28,822,514
Owned by Insiders
7.16%
Owned by Institutions
85.14%

Financial Efficiency

Arcturus Therapeutics’s return on equity (ROE) is -0.31 and return on invested capital (ROIC) is -31.36%.

Return on Equity (ROE)
-0.31
Return on Assets (ROA)
-0.24
Return on Invested Capital (ROIC)
-31.36%
Return on Capital Employed (ROCE)
-0.32
Revenue Per Employee
616.71K
Profits Per Employee
-603.51K
Employee Count
109
Asset Turnover
0.25
Inventory Turnover
0.00

Valuation Ratios

The current PE Ratio of Arcturus Therapeutics is -2.70. Arcturus Therapeutics’s PEG ratio is 0.10.

PE Ratio
-2.70
PS Ratio
9.66
PB Ratio
1.41
Price to FCF
-3.84
Price to Operating Cash Flow
-3.81
PEG Ratio
0.10

Income Statement

In the last 12 months, Arcturus Therapeutics had revenue of 67.22M and earned -65.78M in profits. Earnings per share was -2.40.

Revenue
67.22M
Gross Profit
64.20M
Operating Income
-74.95M
Pretax Income
-65.78M
Net Income
-65.78M
EBITDA
-62.76M
Earnings Per Share (EPS)
-2.40

Cash Flow

In the last 12 months, operating cash flow was -62.48M and capital expenditures -189,660, giving a free cash flow of -62.67M billion.

Operating Cash Flow
-62.48M
Free Cash Flow
-62.67M
Free Cash Flow per Share
-2.20

Dividends & Yields

Arcturus Therapeutics pays an annual dividend of $0.06, resulting in a dividend yield of ―

Dividend Per Share
$0.06
Dividend Yield
―
Payout Ratio
N/A
Free Cash Flow Yield
-26.01%
Earnings Yield
-36.69%

Stock Price Statistics

Beta
2.26
52-Week Price Change
7.59%
50-Day Moving Average
12.43
200-Day Moving Average
9.15
Relative Strength Index (RSI)
36.96
Average Volume (3m)
988.60K

Important Dates

Arcturus Therapeutics upcoming earnings date is Mar 11, 2027, TBA (Not Confirmed).

Last Earnings Date
Nov 05, 2026
Next Earnings Date
Mar 11, 2027
Ex-Dividend Date
Jan 08, 2013

Financial Position

Arcturus Therapeutics as a current ratio of 6.64, with Debt / Equity ratio of 11.68%

Current Ratio
6.64
Quick Ratio
6.64
Debt to Market Cap
0.00
Net Debt to EBITDA
3.28
Interest Coverage Ratio
0.00

Taxes

In the past 12 months, Arcturus Therapeutics has paid 0 in taxes.

Income Tax
0
Effective Tax Rate
0.00

Enterprise Valuation

Arcturus Therapeutics EV to EBITDA ratio is -1.01, with an EV/FCF ratio of -1.24.

EV to Sales
3.13
EV to EBITDA
-1.01
EV to Free Cash Flow
-1.24
EV to Operating Cash Flow
-1.25

Balance Sheet

Arcturus Therapeutics has $184.82M in cash and marketable securities with $21.86M in debt, giving a net cash position of $162.95M billion.

Cash & Marketable Securities
$184.82M
Total Debt
$21.86M
Net Cash
$162.95M
Net Cash Per Share
$5.65
Tangible Book Value Per Share
$5.93

Margins

Gross margin is 97.36%, with operating margin of -384.08%, and net profit margin of -349.71%.

Gross Margin
97.36%
Operating Margin
-384.08%
Pretax Margin
-349.73%
Net Profit Margin
-349.71%
EBITDA Margin
-308.66%
EBIT Margin
-316.61%

Analyst Forecast

The average price target for Arcturus Therapeutics is $21.38, which is 11.43% higher than the current price. The consensus rating is Strong Buy

Price Target
$21.38
Price Target Upside
155.68% Upside
Analyst Consensus
Strong Buy
Analyst Count
9
Revenue Growth Forecast
-74.84%
EPS Growth Forecast
-25.04%

Scores

Smart Score
9
AI Score
47